Clinical trials: Re-irradiation
Non-small Cell Lung Cancer
Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with non-small cell lung cancer (NSCLC) that…
- Trial name
- NCT03087760
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial studies the side effects and best dose of birinapant when given together with intensity modulated re-irradiation therapy (IMRRT) in treating patients with head and neck squamous cell carcinoma that has come…
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
- Trial name
- NCT03803774
- Testing
- Biopsy Procedure, Birinapant, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Pain
Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether single-fraction (single-dose) re-irradiation therapy is as effective as multiple-fraction (many small doses of radiation…
- Trial name
- NCT00080912
- Testing
- radiation therapy
- Where
- 12 sites in Canada
- Volunteers
- 850 people
- Sponsor
- NCIC Clinical Trials Group
Glioblastoma
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: Pembrolizumab Radiation Bevacizumab, an FDA-approved drug for treating recurrent…
- Trial name
- NCT03661723
- Testing
- Pembrolizumab, Bevacizumab, Re-irradiation
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01730950
- Testing
- bevacizumab, radiation therapy
- Where
- 31 sites in United States
- Volunteers
- 182 people
- Sponsor
- Radiation Therapy Oncology Group
Recurrent Glioblastoma
Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.
- Trial name
- ERGO2 (NCT01754350)
- Testing
- calorie-restricted ketogenic diet and transient fasting, standard nutrition
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Breast Cancer
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. It is not yet known whether a single dose of radiation therapy is more effective than implant radiation therapy for 5 days in…
- Trial name
- NCT00945061
- Testing
- intracavitary balloon brachytherapy, intraoperative radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Head and Neck Squamous Cell Carcinoma
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work together in treating patients with head and neck squamous cell cancer that has come back.
- Trial name
- NCT03521570
- Testing
- IMRT, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Emory University
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma of the Head and Neck
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
This trial examines survival and toxicity in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities…
- Trial name
- NCT01104922
- Testing
- Cetuximab, Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- David A. Clump, MD, PhD
Breast Cancer
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery kill any remaining tumor cells and may be an effective treatment for breast cancer.
- Trial name
- NCT01082211
- Testing
- 3D-Conformal External Beam
- Where
- 58 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Radiation Therapy Oncology Group
Ependymoma
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
The primary purpose of this study is to investigate whether surgery and re-irradiation will help treat ependymoma that has come back after initial treatment.
- Trial name
- NCT02125786
- Testing
- Irradiation, Surgery, ^1^8F-Fluorodeoxyglucose
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Head and Neck Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113399
- Testing
- filgrastim, cisplatin, docetaxel
- Where
- 125 sites in United States
- Volunteers
- 15 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
This is a study for patients who have head and neck cancer that has recurred in the body area where they previously received radiation, and for whom surgery is not planned.
- Trial name
- NCT00713219
- Testing
- IMRT, cetuximab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer, Prostatic Neoplasm
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Background: Prostate cancer is the second leading cause of cancer death in United States (U.S.) men. Radiation is an effective treatment for most patients with localized prostate cancer, but sometimes the tumor returns.
- Trial name
- NCT03253744
- Testing
- 18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Metastases, Neoplasm
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
This study will evaluate the effectiveness of chemotherapy and a combination of vaccines to treat metastatic breast cancer (breast cancer that has spread beyond the breast) in patients whose cancer cells have a protein called…
- Trial name
- NCT00048893
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of the Pharynx, Cancer of the Larynx
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms
- Trial name
- NCT00970502
- Testing
- erlotinib + celecoxib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johnny Kao
Recurrent Rectal Cancer
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer
The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.
- Trial name
- IMPARC (NCT04827732)
- Testing
- Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine